Document is current
Any future updates will be listed below
-
Authors
Schurz, Haiko
Solander, Klara
Åström, Davida
Cossío, Fernando
Choi, Taeyang
Dustler, Magnus
Lundström, Claes
Gustafsson, Håkan
Zackrisson, Sophia
Strand, Fredrik
-
Funding
Funding for this research was provided by:
Swedish innovation agency Vinnova
Regional Cancer Centers in Collaboration
Region Stockholm
Swedish Cancer Society
Swedish Research Council
Emil and Wera Cornell Foundation
Lillian Sagens and Curt Ericssons Foundation
- License Information
-
More Information
Article History
Received: 27 August 2024
Accepted: 9 April 2025
First Online: 8 May 2025
Competing interests
: F.S. has received speaker fees from Lunit Inc. and from Pfizer Inc. F.S. and F.C. are major shareholders in ClearScanAI AB. M.D. and S.Z. are patent holders (US patent no. PCT/EP2014/057372) and have received speaker fees from Siemens Healthineers. S.Z. has a research agreement with ScreenPoint Medical. C.L. is an employee and shareholder of Sectra AB. The other authors report no conflict of interest.
